Fast multimodal imaging combined with machine learning identifying taurine as a potential marker for breast cancer margin assessment - Top-Institutions - MDSpire

Fast multimodal imaging combined with machine learning identifying taurine as a potential marker for breast cancer margin assessment

  • By

  • Chunyan Lan

  • Ying Peng

  • Mateng Bai

  • Hengtong Zuo

  • Yue Li

  • Hainan Wu

  • Ting Zhang

  • Xin Zhu

  • Jie He

  • Dan Guo

  • Xiaofang Chen

  • Hongmei Zhao

  • Huafang Gao

  • December 17, 2025

  • 0 min

Share

Top Institutions in General Medicine

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Surgical Oncology
    • Pathology
    • Molecular Imaging
    • Computational Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Oncology
    • Cancer Imaging
    • Translational Research

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Breast Surgical Oncology
    • Cancer Imaging
    • Molecular Pathology

  • #4

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Breast Surgery
    • Pathology
    • Biomedical Imaging

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Breast Oncology
    • Biomedical Imaging
    • Machine Learning in Medicine

Original Source(s)

Fast multimodal imaging combined with machine learning identifying taurine as a potential marker for breast cancer margin assessment

  • by Chunyan Lan, Ying Peng, Mateng Bai, Hengtong Zuo, Yue Li, Hainan Wu, Ting Zhang, Xin Zhu, Jie He, Dan Guo, Xiaofang Chen, Hongmei Zhao, Huafang Gao

  • December 17, 2025

Related Content

Inequities in the Presentation of Disease and the Start of Treatment for De Novo Metastatic Breast Cancer

Effect of race and ethnicity on advanced breast cancer risk prediction model performance

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min